Case Series of 10 Drug-Refractory IBS Patients Who Respond to Oral Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI)
Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=50521#.VECImVfHRK0
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=50521#.VECImVfHRK0
Author(s)
Aim: The responses of 10 patients with
long-standing, symptomatic, intractable drug-refractory histories of
irritable bowel syndrome with diarrhea (IBS-D) and with abdominal pain,
gas/bloating and distention, termed IBS undefined (IBS-U), were
evaluated when administering a medical food product containing
serum-derived bovine immunoglobulin/protein isolate (SBI). Methods:
Patients in this case series were chosen based on their lack of
satisfactory response to a variety of drugs, including antidiarrheal and
antispasmodic medications, serotonin 5-HT3 receptor antagonists,
selective serotonin re-uptake inhibitors (SSRIs), proton pump inhibitors
(PPIs), antibiotics, and antidepressive drugs. Patients met Rome III
criteria and were administered 5 g/day of SBI as standard-of-care
nutritional support. A scale of 0% - 25%, 25% - 50%, 50% - 75%, 75% -
100% response to SBI was used for patient-reported improvement in
overall IBS symptoms following administration for one month. Exact
methods for calculating confidence intervals and p-values were used to
assess complete management of symptoms and response to therapy. Adverse
events were also monitored for this nutritional product. Results: The
onset of gastrointestinal (GI) symptom reduction utilizing nutritional
management with SBI occurred within an average time of 2-4 weeks with
improved or near complete management in all 10 patients who were
refractory to previous drug therapies by 4 weeks. When prompted,
patients reported significant IBS symptom improvement which averaged
between 50% - 100% (p = 0.002) with an average for complete management
in all patients of 69%. No side effects were reported after SBI
administration even when taken for up to 28 weeks. Conclusion: Based on
the safety profile and reported outcomes in this case report, SBI should
be considered as a nutritional option for management in IBS-D and
IBS-U.
KEYWORDS
Cite this paper
Hilal, R. , Mitchell, P. , Guerra Jr., E. and
Burnett, B. (2014) Case Series of 10 Drug-Refractory IBS Patients Who
Respond to Oral Serum-Derived Bovine Immunoglobulin/Protein Isolate
(SBI). Open Journal of Gastroenterology, 4, 321-328. doi: 10.4236/ojgas.2014.410046.
| [1] |
Lovell, R.M. and Ford, A.C.
(2012) Prevalence of Gastro-Esophageal Reflux-Type Symptoms in
Individuals with Irritable Bowel Syndrome in the Community: A
Meta-Analysis. The American Journal of Gastroenterology, 107, 1793-1801.
http://dx.doi.org/10.1038/ajg.2012.336 |
| [2] |
Choung, R.S. and Locke, G.R.
(2012) Epidemiology of IBS. Gastroenterology Clinics of North America,
40, 1-10. http://dx.doi.org/10.1016/j.gtc.2010.12.006 |
| [3] |
Quigley, E.M., et al. (2012) A
global Perspective on Irritable Bowel Syndrome: A Consensus Statement of
the World Gastroenterology Organisation Summit Task Force on Irritable
Bowel Syndrome. Journal of Clinical Gastroenterology, 46, 356-366. http://dx.doi.org/10.1097/MCG.0b013e318247157c |
| [4] |
Hungin, A.P.S., Chang, L.,
Locke, G.R., Dennis, E.H. and Barghout, V. (2005) Irritable Bowel
Syndrome in the United States: Prevalence, Symptom Patterns and Impact.
Alimentary Pharmacology Therapeutics, 21, 1365-1375. http://dx.doi.org/10.1111/j.1365-2036.2005.02463.x |
| [5] |
Drossman, D.A., Camilleri, M.,
Mayer, E.A. and Whitehead, W.E. (2002) AGA Technical Review on Irritable
Bowel Syndrome. Gastroenterology, 123, 2108-2131. http://dx.doi.org/10.1053/gast.2002.37095 |
| [6] |
Camilleri, M. (2012) Peripheral
Mechanisms in Irritable Bowel Syndrome. The New England Journal of
Medicine, 367, 1626-1635. http://dx.doi.org/10.1056/NEJMra1207068 |
| [7] |
Drossman, D.A., Morris, C.B.,
Schneck, S., Hu, Y.J., Norton, N.J., Norton, W.F., Weinland, S.R.,
Dalton, C., Leserman, J. and Bangdiwala, S.I. (2009) International
Survey of Patients with IBS: Symptom Features and Their Severity, Health
Status, Treatments, and Risk Taking to Achieve Clinical Benefit.
Journal of Clinical Gastroenterology, 43, 541-550. http://dx.doi.org/10.1097/MCG.0b013e318189a7f9 |
| [8] | Magge, S. and Lembo, A. (2012) Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome. Gastroenterol Hepatol (NY), 8, 739-745. |
| [9] |
Halmos, E.P., Power, V.A.,
Shepherd, S.J., Gibson, P.R. and Muir, J.G. (2014) A Diet Low in FODMAPs
Reduces Symptoms of Irritable Bowel Syndrome. Gastroenterology, 146,
67-75. http://dx.doi.org/10.1053/j.gastro.2013.09.046 |
| [10] |
Hoveyda, N., Heneghan, C.,
Mahtani, K.R., Perera, R., Roberts, N. and Glasziou, P. (2009) A
Systematic Review and Meta-Analysis: Probiotics in the Treatment of
Irritable Bowel Syndrome. BMC Gastroenterol, 9, 15. http://dx.doi.org/10.1186/1471-230X-9-15 |
| [11] |
Olden, K.W. (2012) Targeted
Therapies for Diarrhea-Predominant Irritable Bowel Syndrome. Clinical
and Experimental Gastroenterology, 5, 69-100. http://dx.doi.org/10.2147/CEG.S29023 |
| [12] |
Petschow, B.W., Burnett, B.P.,
Shaw, A.L., Weaver, E.M. and Klein, G.L. (2014) Dietary Requirement for
Serum-Derived Bovine Immunoglobulins in the Clinical Management of
Patients with Enteropathy. Digestive Diseases and Sciences, Published
Online. http://link.springer.com/article/10.1007%2Fs10620-014-3322-0 http://dx.doi.org/10.1007/s10620-014-3322-0 |
| [13] |
Wilson, D., Evans, M.D., Weaver,
E., Shaw, A.L. and Klein, G.L. (2013) Evaluation of Serum-Derived
Bovine Immunoglobulin Protein Isolate in Subjects with
Diarrhea-Predominant Irritable Bowel Syndrome. Clinical Medicine
Insights: Gastroenterology, 6, 49-60. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020402/pdf/cgast-6-2013-049.pdf |
| [14] | Longstreth, G.F., Thompson, W.G., Chey, W.E., Houghton, L.A., Mearin, F. and Spiller, R.C. (2006) Functional Bowel Disorders. In: Drossman, D.A., Corazziari, E., Delvaux, M., Spiller, R.C., Talley, N.J., Thompson, W.G., et al., Eds., Rome III: The Functional Gastrointestinal Disorders, 3rd Edition, Degnon Associates, McLean, 487-555. |
| [15] |
Talley, N.J., Gabriel, S.E.,
Harmsen, W.S., Zinsmeister, A.R. and Evans, R.W. (1995) Medical Costs in
Community Subjects with Irritable Bowel Syndrome. Gastroenterology,
109, 1736-1741. http://dx.doi.org/10.1016/0016-5085(95)90738-6 |
| [16] |
American Gastroenterological
Association (2001) The Burden of Gastrointestinal Diseases. American
Gastroenterological Association, Bethesda, 1-86. http://www.lewin.com/~/media/Lewin/Site_Sections/Publications/2695.pdf |
| [17] | Martin, R., Barron, J.J. and Zacker, C. (2001) Irritable Bowel Syndrome: Toward a Cost-Effective Management Approach. The American Journal of Managed Care, 7, S268-S275. |
| [18] |
Longstreth, G.F., Wilson, A.,
Knight, K., Wong, J., Chiou, C.F., Barghout, V., Frech, F. and Ofman,
J.J. (2003) Irritable Bowel Syndrome, Healthcare Use, and Costs: A US
Managed Care Perspective. The American Journal of Gastroenterology, 98,
600-607. http://dx.doi.org/10.1111/j.1572-0241.2003.07296.x |
| [19] |
Lieberman, D.A., Holub, J.,
Eisen, G., Kraemer, D. and Morris, C.D. (2005) Utilization of
Colonoscopy in the United States: Results from a National Consortium.
Gastrointestinal Endoscopy, 62, 875-883. http://dx.doi.org/10.1016/j.gie.2005.06.037 |
| [20] |
Longstreth, G.F. and Yao, J.F.
(2004) Irritable Bowel Syndrome and Surgery: A Multivariable Analysis.
Gastroenterology, 126, 1665-1673. http://dx.doi.org/10.1053/j.gastro.2004.02.020 |
| [21] |
Miller, A.R., North, C.S.,
Clouse, R.E., Wetzel, R.D., Spitznagel, E.L. and Alpers, D.H. (2001) The
Association of Irritable Bowel Syndrome and Somatization Disorder.
Annals of Clinical Psychiatry, 13, 25-30. http://dx.doi.org/10.3109/10401230109147126 |
| [22] |
Whitehead, W.E., Palsson, O. and
Jones, K.R. (2002) Systematic Review of the Comorbidity of Irritable
Bowel Syndrome with Other Disorders: What Are the Causes and
Implications? Gastroenterology, 122, 1140-1156. http://dx.doi.org/10.1053/gast.2002.32392 |
| [23] |
Gralnek, I.M., Hays, R.D.,
Kilbourne, A., Naliboff, B. and Mayer, E.A. (2000) The Impact of
Irritable Bowel Syndrome on Health-Related Quality of Life.
Gastroenterology, 119, 654-660. http://dx.doi.org/10.1053/gast.2000.16484 |
| [24] |
Whitehead, W.E., Palsson, O.S.,
Levy, R.R., Feld, A.D., Turner, M. and Von Korff, M. (2007) Comorbidity
in Irritable Bowel Syndrome. The American Journal of Gastroenterology,
102, 2767-2776. http://dx.doi.org/10.1111/j.1572-0241.2007.01540.x |
| [25] |
Jarrett, M., Heitkemper, M.,
Cain, K.C., Burr, R.L. and Hertig, V. (2000) Sleep Disturbance
Influences Gastrointestinal Symptoms in Women with Irritable Bowel
Syndrome. Digestive Diseases and Sciences, 45, 952-959. http://dx.doi.org/10.1023/A:1005581226265 |
| [26] |
Chang, F.Y. and Lu, C.L. (2013)
Irritable Bowel Syndrome and Migraine: Bystanders or Partners? Journal
of Neurogastroenterology and Motillity, 19, 301-311. http://dx.doi.org/10.5056/jnm.2013.19.3.301 |
| [27] |
Sperber, A.D., Akiva, S.,
Leshno, M., Halpern, Z. and Buskila, D. (2011) Validation of New
Symptom-Based Fibromyalgia Criteria for Irritable Bowel Syndrome
Co-Morbidity Studies. Journal of Neurogastroenterology and Motillity,
17, 67-72. http://dx.doi.org/10.5056/jnm.2011.17.1.67 |
| [28] |
Lydiard, R.B., Fossey, M.D.,
Marsh, W. and Ballenger, J.C. (1993) Prevalence of Psychiatric Disorders
in Patients with Irritable Bowel Syndrome. Psychosomatics, 34, 229-234.
http://dx.doi.org/10.1016/S0033-3182(93)71884-8 |
| [29] |
de Bortoli, N., Martinucci, I.,
Bellini, M., Savarino, E., Savarino, V., Blandizzi, C. and Marchi, S.
(2013) Overlap of Functional Heartburn and Gastroesophageal Reflux
Disease with Irritable Bowel Syndrome. World Journal of
Gastroenterology, 19, 5787-5797. http://dx.doi.org/10.3748/wjg.v19.i35.5787 |
| [30] |
Frissora, C.L. and Koch, K.L.
(2005) Symptom Overlap and Comorbidity of Irritable Bowel Syndrome with
Other Conditions. Current Gastroenterology Reports, 7, 264-271. http://dx.doi.org/10.1007/s11894-005-0018-9 |
| [31] |
Petschow, B.W., Burnett, B.,
Shaw, A.L., Weaver, E.M. and Klein, G.L. (2014) Serum-Derived Bovine
Immunoglobulin/Protein Isolate: Postulated Mechanism of Action for
Management of Enteropathy. Clinical and Experimental Gastroenterology,
7, 181-190. http://dx.doi.org/10.2147/CEG.S62823 eww141017lx |
评论
发表评论